

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method for detecting pregnancy-induced hypertension, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject.
2. (Original) The method for detecting pregnancy-induced hypertension according to claim 1, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject and comparing the measured value with a cut-off value that is determined based on measured values of human lipocalin-type prostaglandin D synthase in body fluid samples collected from normal pregnant women and/or pregnant women with pregnancy-induced hypertension.
3. (Original) A method for determining the severity of pregnancy-induced hypertension, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject.

4. (Original) The method for determining the severity of pregnancy-induced hypertension according to claim 3, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject and comparing the measured value with cut-off values that are determined according to the measured values of human lipocalin-type prostaglandin D synthase in the body fluid samples collected from pregnant women with various severities of pregnancy-induced hypertension.

5. (Original) A method for predicting pregnancy-induced hypertension, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject.

6. (Original) The method for predicting pregnancy-induced hypertension according to claim 5, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject showing no hypertension, proteinuria, or edema.

7. (Currently Amended) The method for predicting pregnancy-induced hypertension according to claim 5 or 6, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject and comparing the measured value with a

cut-off value that is determined from measured values of human lipocalin-type prostaglandin D synthase in body fluid samples collected from normal pregnant women and/or pregnant women with pregnancy-induced hypertension.

8. (Original) A method for evaluating a fetus and a placental function, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a patient with pregnancy-induced hypertension.

9. (Currently Amended) The method for detecting pregnancy-induced hypertension according to claim 1 ~~or~~ 2, wherein the level of human lipocalin-type prostaglandin D synthase in a body fluid sample is measured by an immunological assay method.

10. (Currently Amended) The method for determining the severity of pregnancy-induced hypertension according to claim 3 ~~or~~ 4, wherein the level of human lipocalin-type prostaglandin D synthase in a body fluid sample is measured by an immunological assay method.

11. (Currently Amended) The method for predicting pregnancy-induced hypertension according to claim 5 ~~any one of claims 5 to 7~~, wherein the level of human lipocalin-type prostaglandin D synthase in a body fluid sample is measured by an immunological assay method.

12. (Original) The method for evaluating a fetus and a placental function according to claim 8, wherein the level of human lipocalin-type prostaglandin D synthase in a body fluid sample is measured by an immunological assay method.

13. (Currently Amended) The method according to claim 1 ~~any one of claims 1 to 12~~, wherein the body fluid sample is blood.

14. (Currently Amended) The method according to claim 1 ~~any one of claims 1 to 12~~, wherein the body fluid sample is urine.

15. A kit for detecting pregnancy-induced hypertension, which contains an anti-human lipocalin-type prostaglandin D synthase antibody.